Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMEA Biomea Fusion	$1.81 -5.2%	$1.92	$1.29 ▼ $13.07	$68.01M	-0.23	1.13 million shs	2.50 million shs
LYEL Lyell Immunopharma	$8.69 -9.3%	$9.10	$7.65 ▼ $45.42	$128.68M	-0.26	69,322 shs	229,031 shs
PAHC Phibro Animal Health	$23.88 -0.3%	$21.85	$16.16 ▼ $26.55	$967.94M	0.74	207,387 shs	247,450 shs
RNA Avidity Biosciences	$29.31 0.0%	$30.46	$21.51 ▼ $56.00	$3.53B	0.95	1.39 million shs	1.51 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMEA Biomea Fusion	0.00%	-23.31%	+24.83%	-36.93%	-62.68%
LYEL Lyell Immunopharma	0.00%	-10.78%	+2.86%	-24.89%	-79.31%
PAHC Phibro Animal Health	0.00%	-0.21%	+3.74%	+9.04%	+36.61%
RNA Avidity Biosciences	0.00%	-6.57%	-4.87%	-4.96%	-23.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMEA Biomea Fusion	2.4939 of 5 stars	3.6	1.0	0.0	0.0	2.6	2.5	0.6
LYEL Lyell Immunopharma	2.9406 of 5 stars	2.8	3.0	0.0	0.0	1.1	5.0	1.3
PAHC Phibro Animal Health	3.855 of 5 stars	0.8	4.0	2.5	1.1	2.8	3.3	2.5
RNA Avidity Biosciences	2.3329 of 5 stars	4.5	0.0	0.0	0.0	3.2	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMEA Biomea Fusion	3.18	Buy	$21.40	1,082.32% Upside
LYEL Lyell Immunopharma	1.50	Reduce	$20.00	130.15% Upside
PAHC Phibro Animal Health	1.67	Reduce	$20.80	-12.90% Downside
RNA Avidity Biosciences	3.06	Buy	$66.56	127.10% Upside

Current Analyst Ratings Breakdown

Latest RNA, PAHC, LYEL, and BMEA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	RNA Avidity Biosciences	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/16/2025	PAHC Phibro Animal Health	BNP Paribas Exane Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Neutral	$24.00
6/13/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/11/2025	RNA Avidity Biosciences	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Strong-Buy	$65.00
6/10/2025	RNA Avidity Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$70.00 ➝ $75.00
6/10/2025	RNA Avidity Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$57.00 ➝ $59.00
6/10/2025	RNA Avidity Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$57.00 ➝ $59.00
6/9/2025	RNA Avidity Biosciences	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$48.00 ➝ $54.00
6/9/2025	RNA Avidity Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $75.00
6/3/2025	BMEA Biomea Fusion	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$7.00

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$1.42 per share	N/A
LYEL Lyell Immunopharma	$60K	2,144.98	N/A	N/A	$26.21 per share	0.33
PAHC Phibro Animal Health	$1.02B	0.95	$2.11 per share	11.30	$6.34 per share	3.77
RNA Avidity Biosciences	$10.90M	324.08	N/A	N/A	$11.94 per share	2.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMEA Biomea Fusion	-$138.43M	-$3.55	N/A	N/A	N/A	N/A	-197.71%	-134.84%	7/30/2025 (Estimated)
LYEL Lyell Immunopharma	-$342.99M	-$25.00	N/A	N/A	N/A	-514,649.22%	-73.66%	-60.99%	8/6/2025 (Estimated)
PAHC Phibro Animal Health	$2.42M	$0.78	30.62	11.37	0.45	2.68%	30.51%	6.89%	8/27/2025 (Estimated)
RNA Avidity Biosciences	-$322.30M	-$3.00	N/A	N/A	N/A	-4,136.00%	-26.96%	-24.57%	8/8/2025 (Estimated)

Latest RNA, PAHC, LYEL, and BMEA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	LYEL Lyell Immunopharma	-$3.80	-$3.60	+$0.20	-$0.18	N/A	$0.01 million
5/8/2025	Q1 2025	RNA Avidity Biosciences	-$0.88	-$0.90	-$0.02	-$0.90	$2.63 million	$1.60 million
5/7/2025	Q3 2025	PAHC Phibro Animal Health	$0.52	$0.63	+$0.11	$0.51	$352.41 million	$347.80 million
5/5/2025	Q1 2025	BMEA Biomea Fusion	-$0.84	-$0.80	+$0.04	-$0.80	N/A	N/A
3/31/2025	Q4 2024	BMEA Biomea Fusion	-$1.00	-$0.81	+$0.19	-$0.81	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
LYEL Lyell Immunopharma	N/A	N/A	N/A	N/A	N/A
PAHC Phibro Animal Health	$0.48	2.01%	N/A	61.54%	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A

Latest RNA, PAHC, LYEL, and BMEA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/6/2025	PAHC Phibro Animal Health	quarterly	$0.12	2.52%	6/4/2025	6/4/2025	6/25/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMEA Biomea Fusion	N/A	2.25	2.25
LYEL Lyell Immunopharma	N/A	7.49	7.49
PAHC Phibro Animal Health	2.67	2.91	1.23
RNA Avidity Biosciences	N/A	16.91	16.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMEA Biomea Fusion	96.72%
LYEL Lyell Immunopharma	66.05%
PAHC Phibro Animal Health	99.34%
RNA Avidity Biosciences	N/A

Insider Ownership

Company	Insider Ownership
BMEA Biomea Fusion	18.42%
LYEL Lyell Immunopharma	22.30%
PAHC Phibro Animal Health	50.07%
RNA Avidity Biosciences	3.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMEA Biomea Fusion	50	37.57 million	30.65 million	Optionable
LYEL Lyell Immunopharma	270	14.81 million	11.51 million	Optionable
PAHC Phibro Animal Health	1,940	40.53 million	20.24 million	Optionable
RNA Avidity Biosciences	190	120.52 million	115.90 million	Optionable

RNA, PAHC, LYEL, and BMEA Headlines

Recent News About These Companies

Avidity Biosciences’ SWOT analysis: innovative RNA firm eyes 3-drug launch by 2027

June 20 at 3:26 PM | investing.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Sells $27,548.64 in Stock

June 19 at 8:01 AM | insidertrades.com

Wolfe Research Begins Coverage on Avidity Biosciences (NASDAQ:RNA)

June 19 at 1:43 AM | americanbankingnews.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Insider Kathleen P. Gallagher Sells 911 Shares

June 18, 2025 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Trading Up 4.1% - Here's Why

June 17, 2025 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Coverage Initiated at Wolfe Research

June 17, 2025 | marketbeat.com

Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential

June 16, 2025 | investing.com

Avidity Biosciences (NASDAQ:RNA) Shares Down 3.5% - Here's What Happened

June 16, 2025 | marketbeat.com

Assenagon Asset Management S.A. Increases Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)

June 15, 2025 | marketbeat.com

Rhumbline Advisers Increases Stock Holdings in Avidity Biosciences, Inc. (NASDAQ:RNA)

June 14, 2025 | marketbeat.com

GAMMA Investing LLC Has $1.96 Million Stock Position in Avidity Biosciences, Inc. (NASDAQ:RNA)

June 14, 2025 | marketbeat.com

Leerink Partnrs Analysts Decrease Earnings Estimates for RNA

June 14, 2025 | americanbankingnews.com

W. Michael Flanagan Sells 20,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock

June 12, 2025 | marketbeat.com

Leerink Partnrs Has Pessimistic View of RNA FY2026 Earnings

June 12, 2025 | marketbeat.com

Raymond James Initiates Coverage of Avidity Biosciences (RNA) with Strong Buy Recommendation

June 12, 2025 | msn.com

Barclays Forecasts Strong Price Appreciation for Avidity Biosciences (NASDAQ:RNA) Stock

June 12, 2025 | americanbankingnews.com

Avidity Biosciences (NASDAQ:RNA) Stock Price Expected to Rise, Citigroup Analyst Says

June 12, 2025 | americanbankingnews.com

Analysts Offer Predictions for RNA FY2026 Earnings

June 12, 2025 | americanbankingnews.com

Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James

June 11, 2025 | msn.com

Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress

June 11, 2025 | prnewswire.com

Cantor Fitzgerald Weighs in on RNA FY2026 Earnings

June 11, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
By Jeffrey Neal Johnson | June 18, 2025
View 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated
BigBear.ai: Risky AI Stock or Defense Tech Opportunity?
By Jeffrey Neal Johnson | May 28, 2025
View BigBear.ai: Risky AI Stock or Defense Tech Opportunity?
These 3 Stocks Are Buying Back Billions in Shares
By Leo Miller | June 3, 2025
View These 3 Stocks Are Buying Back Billions in Shares

RNA, PAHC, LYEL, and BMEA Company Descriptions

Biomea Fusion NASDAQ:BMEA

$1.81 -0.10 (-5.24%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.82 +0.01 (+0.83%)

As of 06/20/2025 07:49 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Lyell Immunopharma NASDAQ:LYEL

$8.69 -0.89 (-9.29%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$9.10 +0.41 (+4.72%)

As of 06/20/2025 06:03 PM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Phibro Animal Health NASDAQ:PAHC

$23.88 -0.08 (-0.33%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$23.89 +0.01 (+0.04%)

As of 06/20/2025 04:08 PM Eastern

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Avidity Biosciences NASDAQ:RNA

$29.31 -0.01 (-0.03%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$29.56 +0.25 (+0.84%)

As of 06/20/2025 07:24 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time